Summary
AbbVie Inc. announced on September 17, 2019, that it entered into an underwriting agreement to issue and sell €1.4 billion in aggregate principal amount of senior notes. These notes are comprised of €750 million of 0.750% senior notes due 2027 and €650 million of 1.250% senior notes due 2031. The offering is being conducted as a registered public offering and is expected to close on September 26, 2019, subject to customary closing conditions. The primary purpose of this debt issuance is to refinance an upcoming maturity. AbbVie intends to use the net proceeds to redeem, satisfy and discharge, or repay at maturity its €1.4 billion aggregate principal amount of 0.375% senior notes due 2019. Any remaining proceeds will be used for general corporate purposes. This strategic move indicates AbbVie's proactive approach to managing its debt obligations and capital structure.
Key Highlights
- 1AbbVie issued €1.4 billion in senior notes through a public offering.
- 2The notes consist of €750 million due 2027 (0.750% coupon) and €650 million due 2031 (1.250% coupon).
- 3The offering is expected to close on September 26, 2019.
- 4Proceeds will be used to redeem existing 0.375% senior notes due 2019 maturing in the same principal amount.
- 5The refinancing aims to manage upcoming debt maturities and optimize the company's capital structure.
- 6The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification clauses.